Idorsia-led Portfolio

The company will develop each asset to the next inflection point or seek a partner.

Compound Mechanism of action Target indication Status More Information

QUVIVIQ™   (daridorexant)

Dual orexin receptor antagonist

Insomnia

 Commercially available in the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, France, and Sweden; approved throughout the EU

Investor webcast

Lucerastat

Glucosylceramide synthase inhibitor

Fabry disease

 Phase 3 open-label extension study ongoing – kidney biopsy sub-study results expected in Q2 2025 – regulatory pathway to be further discussed with FDA  
Daridorexant Dual orexin receptor antagonist Pediatric insomnia Phase 2 in pediatric insomnia expected to read out results in Q3 2025  
ACT-777991 CXCR3 antagonist Vitiligo Proof-of-concept study in preparation  

ACT-1004-1239

 ACKR3 receptor antagonist Progressive multiple sclerosis Proof-of-concept study in preparation  

IDOR-1117-2520

 CCR6 receptor antagonist

Immune-mediated disorders

 Phase 1 program ongoing.  
ACT-1016-0707 LPA 1 receptor antagonist Immune-mediated and fibrosis related disorders Entry-into-human package complete  
IDOR-1141-8472 Orexin 2 receptor agonist Orexin-related CNS disorders Entry-into-human package ready to begin  
IDOR-1126-6421 Undisclosed mechanism Organ injury Entry-into-human package in progress  

 

Synthetic Glycan Vaccine Platform Idorsia will seek a partner for the platform or individual vaccines
IDOR-1134-2831 Synthetic glycan vaccine Clostridium difficile infection Idorsia is conducting a Phase 1 clinical pharmacology study which has the potential to show whether the vaccine induces an immune response.  Results expected in Q2 2025.
IDOR-1142-0810 Synthetic glycan vaccine Klebsiella pneumonia infection Entry-into-human package in progress.

Partner-led Portfolio

Compound Mechanism of action              Target indication

Partner: Terms

 Status
TRYVIO™ (aprocitentan) Dual endothelin receptor antagonist Systemic hypertension in combination with other antihypertensives To be defined: worldwide development and commercialization rights Commercially available in the US
JERAYGO™ (aprocitentan) Dual endothelin receptor antagonist Resistant hypertension in combination with other antihypertensives To be defined: worldwide development and commercialization rights Approved in the EU and UK; Marketing authorization applications submitted in Canada, and Switzerland
QUVIVIQ™   (daridorexant) Dual orexin receptor 
antagonist		 Insomnia   Nxera Pharma: license to develop and commercialize 
for Asia-Pacific region (excluding China)		 Launched for the treatment of insomnia in Japan; Phase 3 ongoing in South Korea
Daridorexant Dual orexin receptor 
antagonist		 Insomnia   Simcere: license to develop and commercialize
for the Greater China region		 Approved for the treatment of insomnia in Hong-Kong

Selatogrel

P2Y12 inhibitor              

Suspected acute myocardial infarction

Viatris: worldwide development and commercialization rights

Phase 3 “SOS-AMI” program ongoing

Cenerimod

S1P1 receptor modulator   

Systemic lupus erythematosus    

Viatris: worldwide development and commercialization rights (excluding Japan, South Korea, and certain countries in the Asia-Pacific region)

 Phase 3 “OPUS” program ongoing

Daridorexant

Dual orexin receptor antagonist

 Posttraumatic stress
disorder (PTSD)

US Department of Defense (DOD):  Idorsia supports a clinical study sponsored
by the US DOD to develop new therapies to treat PTSD

 Phase 2
ACT-1002-4391 EP2 / EP4 receptor antagonist Immuno-oncology Owkin: global license to develop and 
commercialize		 Phase 1 in preparation
IDOR-1134-9712 CFTR Type-IV corrector Cystic Fibrosis Undisclosed: Option to license following the completion of ongoing entry-into-human package Entry-into-human package in progress